{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:49:06Z","timestamp":1791953346359,"version":"4.3.4"},"reference-count":71,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009447","name":"Leukemia and lymphoma society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"id":[{"id":"https:\/\/ror.org\/0462yrd97","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>S-phase kinase-associated protein 2 (SKP2), a key substrate-recognition subunit of the Skp1-Cul1-F-box (SCF) E3 ubiquitin ligase complex, promotes the ubiquitin\u2013proteasome-mediated degradation of tumor suppressors such as p27Kip1 and p21(Cip1\/Waf1). Through these activities, SKP2 regulates critical cellular processes, including cell cycle progression, apoptosis, metabolic reprogramming, maintenance of cancer stem cell stemness, and contributes to the pathogenesis, therapeutic resistance, and clinical progression of hematological malignancies. Recent advances in protein degradation technologies and regulatory network analysis have highlighted SKP2 and its substrate interactions as promising targets for precision therapies. In this review, we examine the biological functions of SKP2 and regulatory mechanisms governing its substrate spectrum across hematological malignancies, including acute myeloid leukemia, chronic myeloid leukemia, B\/NK\/T-cell lymphoma, and multiple myeloma. We further review currently available SKP2-targeted therapeutic strategies, including small-molecule inhibitors, molecular glue degraders, and proteolysis-targeting chimeras (PROTACs), and discuss SKP2-related prognostic biomarkers in hematological malignancies. Finally, we outline the key challenges and future directions to guide the development of SKP2-centered therapeutic approaches.<\/jats:p>","DOI":"10.3390\/cells15191796","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:19:08Z","timestamp":1790842748000},"page":"1796","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The SKP2\u2013Substrate Axis in Hematological Malignancies: Mechanisms of Oncogenesis and Opportunities for Targeted Therapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Yueying","family":"Zhang","sequence":"first","affiliation":[{"name":"Laboratory Medicine Program, Department of Laboratory Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Pathophysiology, College of Clinical and Basic Medicine, Shandong First Medical University, Jinan 250017, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2951-4286","authenticated-orcid":false,"given":"Omar","family":"Faruq","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Program, Department of Laboratory Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-2682","authenticated-orcid":false,"given":"Shamila D.","family":"Alipoor","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, Link\u00f6ping University, SE-581 83 Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Program, Department of Laboratory Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103193","DOI":"10.1016\/j.eclinm.2025.103193","article-title":"Global landscape and trends in lifetime risks of haematologic malignancies in 185 countries: Population-based estimates from GLOBOCAN 2022","volume":"83","author":"Sun","year":"2025","journal-title":"EClinical Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12967-025-07610-z","article-title":"Targeted protein degradation: Species, diseases and efficient utilization","volume":"24","author":"Yue","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrc1881","article-title":"Ubiquitin ligases: Cell-cycle control and cancer","volume":"6","author":"Nakayama","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets","volume":"10","author":"Bedford","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-025-02392-8","article-title":"Targeting ubiquitination in disease and therapy","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107579","DOI":"10.1016\/j.pharmthera.2020.107579","article-title":"The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges","volume":"213","author":"Tundo","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41580-018-0040-z","article-title":"Regulation of proteasome assembly and activity in health and disease","volume":"19","author":"Rousseau","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0092-8674(95)90271-6","article-title":"P19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase","volume":"82","author":"Zhang","year":"1995","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(00)80098-7","article-title":"SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box","volume":"86","author":"Bai","year":"1996","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molcel.2005.09.003","article-title":"Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase","volume":"20","author":"Hao","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1182\/blood.V100.8.2950","article-title":"Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: Correlation with p27(Kip1) and proliferation index","volume":"100","author":"Lim","year":"2002","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-04-0136","article-title":"Elevated S-phase kinase-associated protein 2 protein expression in acute myelogenous leukemia: Its association with constitutive phosphorylation of phosphatase and tensin homologue protein and poor prognosis","volume":"10","author":"Min","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ajh.10379","article-title":"Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma","volume":"73","author":"Seki","year":"2003","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/annonc\/mdp481","article-title":"Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: Effects of rituximab","volume":"21","author":"Seki","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37838","DOI":"10.1038\/s41598-025-21719-7","article-title":"Targeting of SKP2 to combat drug resistance in multiple myeloma","volume":"15","author":"Faruq","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5732\/cjc.009.10645","article-title":"The role of Skp2 in extranodal NK\/T-cell lymphoma","volume":"29","author":"Guo","year":"2010","journal-title":"Chin. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.trsl.2008.04.004","article-title":"Skp2\/p27 expression profile is correlated with Epstein-Barr virus status in extranodal nasal-type natural killer cell lymphoma","volume":"151","author":"Dan","year":"2008","journal-title":"Transl. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/leu.2016.258","article-title":"Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes bortezomib resistance in multiple myeloma","volume":"31","author":"Malek","year":"2017","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e8412","DOI":"10.1590\/1414-431x20198412","article-title":"Skp2 inhibitor SKPin C1 decreased viability and proliferation of multiple myeloma cells and induced apoptosis","volume":"52","author":"Yang","year":"2019","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood-2007-09-112904","article-title":"Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41587-025-02793-8","article-title":"A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2","volume":"44","author":"Chu","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1021\/acs.jmedchem.5c03213","article-title":"Natural Product-Inspired PROTACs for Leukemia Therapy: Hederagenin-Driven Targeted Degradation of SKP2","volume":"69","author":"Chen","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jing, J., Rui, L., Junyuan, S., Jinfeng, Y., Zhihao, H., Weiguo, L., and Zhenyu, J. (2023). Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1122008"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40364-024-00638-1","article-title":"Targeted protein degradation in hematologic malignancies: Clinical progression towards novel therapeutics","volume":"12","author":"Feng","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/cncr.23317","article-title":"Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer","volume":"112","author":"Hershko","year":"2008","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41422-020-0372-z","article-title":"Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle","volume":"31","author":"Liu","year":"2021","journal-title":"Cell Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2013.06.048","article-title":"Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression","volume":"154","author":"Chan","year":"2013","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1038\/onc.2017.64","article-title":"Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist","volume":"36","author":"Ruan","year":"2017","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.7150\/jca.95266","article-title":"Raddeanin A (RA) Inhibited EMT and Stemness in Glioblastoma via downregulating Skp2","volume":"16","author":"Jia","year":"2025","journal-title":"J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"baf022","DOI":"10.1093\/pcmedi\/pbaf022","article-title":"A pan-cancer analysis revealed SKP2 as an inhibitor of the tumor immune microenvironment and a promising therapeutic target for immunotherapy","volume":"8","author":"Liao","year":"2025","journal-title":"Precis Clin. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semcancer.2020.01.013","article-title":"The Skp2 Pathway: A Critical Target for Cancer Therapy","volume":"67","author":"Cai","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"William, J.N.G., Dhar, R., Gundamaraju, R., Sahoo, O.S., Pethusamy, K., Raj, A.F.P.A.M., Ramasamy, S., Alqahtani, M.S., Abbas, M., and Karmakar, S. (2024). SKping cell cycle regulation: Role of ubiquitin ligase SKP2 in hematological malignancies. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1288501"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.stem.2011.07.003","article-title":"P57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70","volume":"9","author":"Zou","year":"2011","journal-title":"Cell Stem Cell"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wu, T., Gu, X., and Cui, H. (2021). Emerging Roles of SKP2 in Cancer Drug Resistance. Cells, 10.","DOI":"10.3390\/cells10051147"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"34715","DOI":"10.1038\/s41598-025-18456-2","article-title":"SKP2 regulates TERT independently of RUNX1\/ETO in AML subtypes lacking the t(8,21) translocation via CDKN1B and RB phosphorylation states","volume":"15","author":"Azlan","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1038\/s41388-019-0955-7","article-title":"Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin","volume":"38","author":"Yu","year":"2019","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"120231","DOI":"10.1016\/j.lfs.2021.120231","article-title":"Skp2 promotes APL progression through the stabilization of oncoprotein PML-RAR\u03b1 and the inhibition of JunB expression","volume":"289","author":"Dan","year":"2022","journal-title":"Life Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-04-1357","article-title":"BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells","volume":"65","author":"Andreu","year":"2005","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2007-09-113860","article-title":"Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease","volume":"112","author":"Agarwal","year":"2008","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bao, J., Freund, O., Sund, L., and Du, W. (2026). Inside the Battle Against Acute Myeloid Leukemia: Biology, Breakthroughs, and Hope. Cells, 15.","DOI":"10.3390\/cells15040338"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1182\/blood-2010-11-321521","article-title":"The SKP2 E3 ligase regulates basal homeostasis and stress-induced regeneration of HSCs","volume":"117","author":"Rodriguez","year":"2011","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"eabn3248","DOI":"10.1126\/scitranslmed.abn3248","article-title":"CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia","volume":"14","author":"Grey","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature07618","article-title":"Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells","volume":"457","author":"Viale","year":"2009","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1182\/blood-2010-10-312785","article-title":"The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hodeib, H., Abd El Hai, D., Tawfik, M.A., Allam, A.A., Selim, A.F., Sarhan, M.E., Selim, A., Sabry, N.M., Mansour, W., and Youssef, A. (2022). The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia. Genes, 13.","DOI":"10.3390\/genes13060948"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"173366","DOI":"10.1016\/j.ejphar.2020.173366","article-title":"Targeting SKP2\/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation","volume":"883","author":"Liu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12967-016-0823-y","article-title":"Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells","volume":"14","author":"Iskandarani","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.2147\/CMAR.S253367","article-title":"Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib","volume":"12","author":"Chen","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/cbin.11779","article-title":"Inhibition of Skp2 enhances doxorubicin-induced cell death in B cell precursor acute lymphoblastic leukemia","volume":"46","author":"Chegeni","year":"2022","journal-title":"Cell Biol. Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1128\/MCB.25.5.1749-1763.2005","article-title":"SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen","volume":"25","author":"Knight","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/j.yexcr.2007.04.027","article-title":"Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines","volume":"313","author":"Dohda","year":"2007","journal-title":"Exp. Cell Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41375-019-0653-z","article-title":"Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL","volume":"34","author":"Rodriguez","year":"2020","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/path.2433","article-title":"S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma","volume":"216","author":"Uddin","year":"2008","journal-title":"J. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood.2023019758","article-title":"Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis","volume":"142","author":"Poos","year":"2023","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0002-9440(10)62571-0","article-title":"S-phase kinase-associated protein 2 expression in non-Hodgkin\u2019s lymphoma inversely correlates with p27 expression and defines cells in S phase","volume":"160","author":"Chiarle","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Rana, P.S., Goparaju, K., and Driscoll, J.J. (2023). Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1141851"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1159\/000520312","article-title":"Multiple Myeloma: Molecular Pathogenesis and Disease Evolution","volume":"44","author":"Heider","year":"2021","journal-title":"Oncol. Res. Treat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/leu.2014.255","article-title":"Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma","volume":"29","author":"Yang","year":"2015","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e00238\u201319","DOI":"10.1128\/JVI.00238-19","article-title":"Mechanisms of B-Cell Oncogenesis Induced by Epstein-Barr Virus","volume":"93","author":"Saha","year":"2019","journal-title":"J. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"51362","DOI":"10.1074\/jbc.M405944200","article-title":"Molecular and biochemical characterization of the Skp2-Cks1 binding interface","volume":"279","author":"Wang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"178129","DOI":"10.1016\/j.ejphar.2025.178129","article-title":"Targeting the Skp2-Cks1 protein-protein interaction: Structures, assays, and preclinical inhibitors","volume":"1006","author":"Kamel","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"117788","DOI":"10.1016\/j.ejmech.2025.117788","article-title":"Molecular hybridization strategy\u2014Discovery of 2,3-diarylpyrazine derivatives as potent Skp2 inhibitors with improved anti-tumor activity and enhanced cisplatin sensitivity","volume":"295","author":"Hu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_66","unstructured":"University of Illinois at Chicago (2026, September 26). Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia). ClinicalTrials.gov Identifier: NCT00346502, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00346502."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1111\/cas.15005","article-title":"Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer","volume":"112","author":"He","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"108134","DOI":"10.1016\/j.phrs.2026.108134","article-title":"Pevonedistat targeting NEDDylation activating enzyme for human diseases: Underlying mechanisms, clinical studies, and future directions","volume":"225","author":"Fu","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lan, C., Ni, B., Zhao, T., Li, Z., Wang, J., Ma, Y., Li, W., and Wang, X. (2022). An integrative pan-cancer analysis revealing MLN4924 (Pevonedistat) as a potential therapeutic agent targeting Skp2 in YAP-driven cancers. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.866702"},{"key":"ref_70","unstructured":"Takeda (2026, September 26). Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Higher-Risk Myelodysplastic Syndromes (HR-MDS), Chronic Myelomonocytic Leukemia (CMML), Or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER). ClinicalTrials.gov Identifier: NCT03268954, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03268954."},{"key":"ref_71","unstructured":"Children\u2019s Oncology Group (2026, September 26). Pevonedistat, Irinotecan, and Temozolomide in Treating Patients with Recurrent or Refractory Solid Tumors or Lymphoma. ClinicalTrials.gov Identifier: NCT03323034, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03323034."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/19\/1796\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:22:24Z","timestamp":1791951744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/19\/1796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":71,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cells15191796"],"URL":"https:\/\/doi.org\/10.3390\/cells15191796","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}